Inferra AI / Company / IRMD / Slides
Iradimed Corp — View Slides (company IR deck)
Iradimed Corp (IRMD) · 17 slides · Filed Oct 30, 2026
Every slide of this earnings presentation, with the text as published. Open the original deck ↗ · All IRMD deck slides
Slide 1 — Investor Presentation
INNOVATORS IN MRI PATIENT CARE Investor Presentation October 2025
Slide 2 — Forward -Looking Statements
2 Forward -Looking Statements This presentation contains a financial outlook for the full year 2025 and other forward-looking statements (i.e., statements that are not historical facts). Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date that they are made, which reflect management's current estimates, projections, expectations, or beliefs, and which involve risks and uncertainties that could cause actual results and outcomes to be materially different. Risks and uncertainties that may affect the future results of the company include, but are not limited to, potential disruptions in our limited supply chain for our products; the Company’s ability to receive FDA 510(k) clearance for new products and product candidates; unexpected costs, delays or diversion of management’s attention associated with the design, manufacture or sale of new products; the Company’s ability to implement successful sales techniques for existing and future products and evaluate the effectiveness of its sales techniques; additional actions, warnings or requests from the FDA or other regulatory bodies; our significant reliance on a limited number of products; a reduction in international distribution; actions of the FDA or other regulatory bodies that could delay, limit or suspend product development, manufacturing or sales; the effect of recalls, patient adverse events or deaths on our business; difficulties or delays in the development, production, manufacturing and marketing of new or existing products and services; changes in laws and regulations or in the interpretation or application of laws or regulations. Further information on these and other factors that could affect the Company’s financial results is included in filings we make with the Securities and Exchange Commission from time to time. All forward-looking statements are based on information available to us on the date hereof, and we assume no obligation to update forward-looking statements.
Slide 3 — MRI
3 We Are MRI PATIENT CARE Non-Magnetic • Portable MRI IV Infusion Pump • Portable MRI Patient Monitor • MRI Room Entry Safety - FMD 3 Safety in MRI
Slide 4 — Strong Revenue
4 Strong Revenue ~$73M in 2024 Guidance of $80M- $82.5M in 2025 Highly Profitable Gross margins (>75%) and operating margins (>25%) Solid Growth Double-digit revenue growth Robust Balance Sheet $53M cash @ June 30, 2025, with no debt Return of Capital Delivering returns to our investors via a $.17 quarterly dividend
Slide 5 — Iradimed Timeline
5 Iradimed Timeline 2012 Iradimed begins selling the 2nd-gen 3860 IV pump through a direct sales force 2014 IRMD Initial Public Offering on Nasdaq 1987 Roger Susi founds Invivo Research, and develops the world’s 1st MRI patient monitor, the 3100 Omni-Trak 2016 The IRadimed 3880 1st non-magnetic patient monitoring solution, designed to move with the patient between their care unit and the MRI suite while safely maintaining the ‘continuity of care’ 2005 Susi founds Iradimed after the sale of Invivo and develops the world’s 1st MRI- compatible IV pump, the 3850 2025 The Iradimed 3870 Next- Gen IV infusion pump is slated for release to the market in late 2025. 1996 Susi and his Invivo team develop specialized wireless technology in MRI with the 3150 Omni-Trak
Slide 6 — MRI Environment Challenge
6 MRI Environment Challenge Equipment Risks • Ferrous components create hazards • Device performance altered by magnetic field • Burn risk from conductive materials (wire danger) • Image artifact interferes with diagnosis – RF noise FDA Reported MRI Adverse Event Types1 Thermal Mechanical Projectile Image Quality Misc. Acoustic Unclear 58% 11% 9% 6% 6% 6% 4% 1: MRI-related FDA Adverse Event Reports: a 10 Year Review, 2019 Why a special niche?
Slide 7 — The Solution for MRI Workflow Challenge : MRI
7 The Solution for MRI Workflow Challenge : MRI -Safe Devices in Critical Care Reduction in Time ‘Off Unit’ Continuity of Care Efficient Use of the MRI Scanner and Increased Patient Throughput Expedited MRI Diagnosis Bedside Set-Up Transport MRI Exam Return Post MRI Connect the MRI-safe monitor and IV pump at patient location Seamless care during patient transfer back Lightweight MRI safe devices enable smooth patient transfer Non-magnetic MRI safe devices support safe imaging Back to bedside as patient is switched to a non-MRI monitor and IV pump Key Benefits
Slide 8 — Our Foundational Product - iRadimed 3860+
Our Foundational Product - iRadimed 3860+ Non-Magnetic IV Infusion Pump System • No direct competition • Wireless remote display • Average mid -70% gross margins • Proprietary IV sets provide a recurring revenue component • Current global install base ~ 13,500 IV channels • Initial market assumption based on 1 IV pump for every 1 MRI • Discovered opportunity for pumps as workflow solution leads to multiple device orders by customers (multiplier effect) 8
Slide 9 — Upcoming Next-Gen IV Pump Launch Provides Large Revenue Opportunity
9 Introduces an enhanced, intuitive graphical touchscreen user interface Smartspinethatlinkstogethera maximum of fourpumpsonone non-magneticIV pole Moderndrug librarythat accommodates multiplepatientcare areas drug listing Multiple pumpsdockedtogether can be controlled froma singlewireless touchscreen remotecontrol No competitive product on the market MRIdium 3870 Next-Gen Non-Magnetic IV Pump Solution Upcoming Next-Gen IV Pump Launch Provides Large Revenue Opportunity Significant replacement potential for the next-genpumpas a largeportionof the existing installed base will be reaching their end of lifespan(~5 years) — Installbaseequatesto ~13,500existing pumpchannels globally Improvedproductdesignof the new pump provides a greenfield expansionopportunity throughhigheradoption by new customers Key Features Market Opportunity — ~ 6,000 pump channels in the U.S. are estimated to be at or nearing the end of their lifespan (≥ 5 years old)
Slide 10 — IRadimed 3880
10 IRadimed 3880 Non-Magnetic Patient Monitor • Only Portable and Non-magnetic MR monitor • Highly advanced “homegrown” piezo technology • Average mid -70% gross margins • Proprietary electrodes and disposables provide a recurring revenue component Product Opportunity/Growth • One direct competitor – Invivo (Phillips) • Current Install base ~ 3,800 • Portability allows for unique solutions to MRI workflow challenges and expands market opportunity as seen in the pump market (multiplier effect)
Slide 11 — Established Market with Significant Roomto Grow
11 Established Market with Significant Roomto Grow 3 Global Existing MRI Scanner Base Supported by Strong Fundamentals All MRI Scanners ~38,000 MRI Scanners High Acuity Hospitals ~26,700 MRI Scanners Critical Care ~24,800 Multiplier Opportunity Pump ~13,500 Current IV Channels Install Base ~3,800 Current Install Base Current IRadimed Install Base ~100M MRI scans performed worldwide each year 1 of 5 ICU patients in the US require an MRI scan Multiplier opportunity within core critical care departments / high acuity settings Monitor
Slide 12 — Technical Expertise and Intellectual Property
12 Technical Expertise and Intellectual Property • Breakthrough use of piezo ceramic Ultrasonic Motive technique • Non-magnetic and RF-quiet medical device design • MRI wireless connectivity – custom radio design • 20 issued patents and two pending patents
Slide 13 — Commercial Strategy
13 Commercial Strategy • Continue expansion of MRI-focused U.S. direct sales force and our international sales efforts • 30 U.S. territories • 3 International sales personnel • 80+ countries with distribution channels • Provide best-in-class customer service and user experience – 10 U.S. field clinical specialists
Slide 14 — Proven Track Record of Growth and Profitability
14 Proven Track Record of Growth and Profitability
Slide 15 — Iradimed Executive Team
15 Iradimed Executive Team Roger Susi PRESIDENT AND CHIEF EXECUTIVE OFFICER Jack Glenn CHIEF FINANCIAL OFFICER Jeff Chiprin CHIEF COMMERCIAL OFFICER
Slide 16 — Iradimed Highlights
16 Iradimed Highlights Disruptive Patient Monitoring Technology Platform that Addresses the Challenges of MRI Workflow Uniquely Positioned to Capitalize on a Global Market Opportunity Across Pumps and Monitors Highly Protected and Differentiated Product Portfolio with Very Limited Competition in the Monitor Space and No Competition for MRI IV Pump Space Upcoming Launch of Next-Gen Pump Will Further Catalyze Growth 5 Demonstrated Track Record of Top-Line Growth and Increasing Profitability 2 3 4 1
Slide 17 — Thank You
INNOVATORS IN MRI PATIENT CARE Thank You [email protected]